What's New


License Agreement Has Been Entered into with Heartseed Inc.

We have executed a worldwide license agreement with Heartseed Inc. (Tokyo, Japan) for the use of iPS cell-derived cardiomyocytes products for regenerative therapy under the patents on iPS cell related technologies licensed to us by Kyoto University.

Heartseed Inc.

Back to top